PedAM
Pediatric Disease Annotations & Medicines
| Disease | breast cancer |
| Symptom | C0730345|microalbuminuria |
| Sentences | 1 |
| PubMedID- 20480148 | Renal safety has been confirmed, without clinically relevant changes in serum creatinine, creatinine clearance, or microalbuminuria, in patients with breast cancer and bone metastases receiving ibandronate 6 mg every 3–4 weeks for 6 months given over 15 min or for 2 years given every 3–4 weeks over 1–2 h . |
Page: 1